Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $16.45, for a total value of $98,700.00. Following the transaction, the general counsel now owns 105,386 shares of the company’s stock, valued at $1,733,599.70. The trade was a 5.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Centessa Pharmaceuticals Price Performance

CNTA opened at $16.77 on Thursday. The company’s 50-day simple moving average is $16.46 and its two-hundred day simple moving average is $16.36. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09. The stock has a market capitalization of $2.21 billion, a P/E ratio of -10.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $2,834,000. Wellington Management Group LLP bought a new position in Centessa Pharmaceuticals in the third quarter valued at about $1,609,000. State Street Corp purchased a new position in Centessa Pharmaceuticals in the third quarter worth about $777,000. Ally Bridge Group NY LLC bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $4,951,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $4,305,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.